Junkies Don’t Exist
.
I’ll never forget the time a relative casually called me a “junkie,” as I organised my collection of drugstore makeup…
Europe
Latest Posts From
Europe
How Gender Affirming Care Is Harm Reduction
.
The nature of the trans experience for me, and many, is of being forcibly politicised from a young age. Our…
How the EU Makes Drug Policies
.
The way that the European Union (EU) creates drug policy can seem unclear given its many levels of decision- and…
UK Harm Reduction: The Origins of Release
.
As drug policy concerns become progressively more salient and relevant to a much larger and increasingly global population, interested people…
Beyond the Trip: Key Challenges The Psychedelic Industry Must Face
.
In the context of the psychedelic renaissance, a significant body of medical research has developed, exploring how psychoactive plants could…
Good Business Skills Aren’t Respected In Cannabis
.
Business is everywhere. I have always been fascinated with the concept of Business ever since I was a young boy:…
Review: ‘How to Regulate Psychedelics: A Practical Guide’
.
The psychedelic renaissance has been propelled forward by its newfound compatibility with mainstream market forces in the West: self-driven improvements…
The Problem With Viewing Addiction As Inevitable
.
I won’t deny that accepting the one real inevitability in life (i.e., that all mortals must eventually die) is philosophically…
From Ego to Eco: The Environmentally Transformative Power of Psychedelics
.
Psychedelics have long been a subject of fascination and controversy. From their use in ancient rituals to their resurgence in…
Scotland, European Capital of Overdoses, Will Open A Drug Consumption Room
.
On September 27th, a joint committee formed by NHS and city council officers approved a plan to implement Scotland’s first…
Making Sense of the EU’s New Drug Policy – Part 2
.
Optimistic thoughts for a progressive EU drug policy (This is part 2 out of 2 of a series of posts…
Making Sense of the EU’s New Drug Policy – Part 1
.
Will EU drug policymaking become reactionary? (This is part 1 out of 2 of a series of posts on the…